Slows the rate at which food leaves the stomach, helping you feel satisfied for longer after meals
Risks And Contraindications GLP 1 therapy can cause nausea, early fullness, reflux, constipation, or diarrhea, most often during dose increases
Wegovy Shot (Injectable Formulation) The Wegovy injection received FDA approval in June 2021 for chronic weight management
10.1016/j.tem.2011.12.008 12 FrosstP.BlomH.MilosR.GoyetteP.SheppardC.MatthewsR.et al
They observed a significant increase in serum adiponectin levels after liraglutide, while exenatide had no effect, which is consistent with our results
Citations [1] Mikus D, Sikiric P, Seiwerth S, Petricevic A, Aralica G, Druzijancic N, Rucman R, Petek M, Pigac B, Perovic D, Kolombo M, Kokic N, Mikus S, Duplancic B, Fattorini I, Turkovic B, Rotkvic I, Mise S, Prkacin I, Konjevoda P, Stambuk N, Anic T